The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.